Recently I have received several e-mails and had many patients ask me about the topic of inflammatory breast cancer. Also, ...
SurvivorNet on MSN
'Practice-changing': FDA approves Ibrance combination as new maintenance option for HR+/HER2+ metastatic breast cancer
The FDA has approved palbociclib (Ibrance) in combination with trastuzumab (Herceptin), endocrine therapy, and optionally ...
These 8 healthcare stocks delivered strong gains last week. Discover what drove each rally—and why not all rallies are ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results